David C. Seldin
Amyloid Treatment and Research Program
Department of Medicine
Boston University School of Medicine
Boston
USA
Name/email consistency: high
- CK2 as a positive regulator of Wnt signalling and tumourigenesis. Seldin, D.C., Landesman-Bollag, E., Farago, M., Currier, N., Lou, D., Dominguez, I. Mol. Cell. Biochem. (2005)
- Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Seldin, D.C., Anderson, J.J., Sanchorawala, V., Malek, K., Wright, D.G., Quillen, K., Finn, K.T., Berk, J.L., Dember, L.M., Falk, R.H., Skinner, M. Blood (2004)









